CRISPR Archives -

The potential of CRISPR technology has been a hot topic in the industry ever since it was first

CRISPR therapies targeting the next breakthrough in oncology

https://pharmaphorum.com/r-d/crispr-therapies-targeting-the-next-breakthrough-in-oncology/

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

Phil Taylor Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering 0 Comment

Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed

Bayer trumpets $1bn CRISPR deal with Mammoth Bio

https://pharmaphorum.com/news/bayer-trumpets-crispr-deal-mammoth-bio/

R&D/ Views & Analysis/ Views and analysis

Pharma’s use of synthetic biology could deliver radical innovation

mike.hammerton@pharmaphorum.com Biotech, CRISPR, Debiopharm, Debiopharm Innovation Fund, synthetic biology 0 Comment

Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways

Pharma’s use of synthetic biology could deliver radical innovation

https://pharmaphorum.com/r-d/pharma-synthetic-biology-radical-innovation/

News/ News/ R&D

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

Richard Staines CRISPR, CRISPR Therapeutics, Editas, gene editing, Vertex 0 Comment

CRISPR Therapeutics is to receive a hefty $900m payment from Vertex after the companies amended a collaboration to

Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal

https://pharmaphorum.com/news/nobel-winner-charpentiers-crispr-therapeutics-gets-900m-in-reworked-vertex-deal/

R&D/ Views & Analysis/ Views and analysis

Casting aside CRISPR scissors and making a point with base editors

mike.hammerton@pharmaphorum.com CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta 0 Comment

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at

Casting aside CRISPR scissors and making a point with base editors

https://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/

R&D/ Views & Analysis/ Views and analysis

Gene editing: beyond the hype

George Underwood CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo 0 Comment

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles

Gene editing: beyond the hype

https://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/

RNA Editing Summit - PharmaPhorum Banner Final

Events/ Events/ R&D

2nd RNA Editing Summit 2020

Kaltrina Kastrati CRISPR, Genome Editing, rna editing, Wave LifeSciences

Industry led meeting on RNA Editing mechanisms

2nd RNA Editing Summit 2020

https://pharmaphorum.com/events/2nd-rna-editing-summit-2020/

Partner Content/ Partner content/ Press releases

4th Annual Genome Editing USA Congress

Bradley Copeman cas9, CRISPR, gene editing, Genome Editing, Genome Engineering 0 Comment

2 days, 350+ end users, 80+ case studies

4th Annual Genome Editing USA Congress

https://pharmaphorum.com/partner-content/4th-annual-genome-editing-usa-congress/

News/ News/ R&D

GSK makes CRISPR play, funding Doudna lab in California

Phil Taylor CRISPR, GSK, research lab 0 Comment

GlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new

GSK makes CRISPR play, funding Doudna lab in California

https://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/

Trending

CRISPR

Login